Close

Bristol-Myers Squibb (BMY), Enterome Enter Immuno-Oncology Collaboration for Microbiome-Derived Biomarkers Development

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. TSLA
2. GM
3. SPY
4. SPOT
5. SHW
6. AMZN
7. AAPL
8. NVDA
9. MTTR
10. IBM


Go back to Bristol-Myers Squibb (BMY), Enterome Enter Immuno-Oncology Collaboration for Microbiome-Derived Biomarkers Development

Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules

November 16, 2016 3:00 AM EST

NEW YORK & PARIS--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Enterome, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused... More